Laboratory of Virology and Electron Microscopy – Experimental Institute of Lombardy and Emilia Romagna.
TESTS FOR EVALUATION OF THE INACTIVATING POWER OF SILVER SYNTHAG TOWARDS THE BETA-CORONAVIRUS BELONGING TO THE SAME KIND OF SARS-COV-2.
In the toxicity check of the silver inactivating substance SynthAg no toxic effect was detected on the tested HRT-18 cells (IZSLER protocol n. 241549/2020).
In the assessment of the persistence of the inactivating power of SynthAg silver (IZSLER protocol no. 241549/2020) for 48h on the B-CoV 10 TCID50 / ml beta-coronavirus virus, the absence of viral growth was found.
In conclusion, the tested SynthAg silver proved to be able to totally inactivate a viral suspension of a beta coronavirus B-CoV containing 10 TCID5dml after the three expected contact times: 1O min .; 30min; 60min. Furthermore, the persistence of the inactivating power of SynthAg silver after 48 hours has been demonstrated.
30min; 60min. Inoltre, è stata dimostrata la persistenza del potere inattivante dell’argento SynthAg dopo 48 ore.
The US Environmental and Health Protection Agency (EPA) has identified a list of substances that can help protect against the human coronavirus. Silver is included along with other substances.
The listed substances can destroy SARS-CoV-2, as they have been shown to be effective against harder-to-kill viruses, as well as the human coronavirus, similar to SARS-CoV-2.
Potential antiviral agents
In 2011, a group of Italian scientists published a large study that showed that nanosilver can resist different types of viruses: hepatitis B virus, herpes simplex virus, human parainfluenza, respiratory syncytial virus and smallpox virus. monkeys.
The use of silver nanoparticles opens up interesting possibilities for new antiviral treatments. Since nanosilver has the ability to attack the virus in different ways, there is a lower chance of developing resistance than conventional antiviral drugs .
The nanosilver prevents the development of HIV
In January 2010, an article was published in the journal Nanobiotechnology in which Mexican immunologists from the University of Nuevo Leon studied the effectiveness of silver nanoparticles against HIV.
They found that nanosilver blocks HIV entry into cells and stops the virus from developing in the early stages and reduces the possibility of infection being transmitted between cells. 
Silver nanoparticles against the influenza A virus.
The H1N1 A virus, also known as the “swine flu”, is the most common type of flu that has killed more than 50 million people. It is he who causes the greatest epidemics, infecting people and animals. There have been several outbreaks of this flu, which was the cause of the pandemic in 1918 (Spanish flu) and 2009 (swine flu).
The virucidal activity of silver nanoparticles has been demonstrated against a wide range of viruses. In most cases, there is a direct interaction between the nanoparticle and the surface proteins of the virus .
The vast majority of people around the world get seasonal flu without serious complications, sometimes even without medication. But severe influenza is characterized by primary viral pneumonia, which is insensitive to antibiotics and can be fatal within 24 hours. Japanese scientists conducted a study on the effect of silver nanoparticles on influenza A and evaluated their antiviral activity. They mixed virus and nanoparticle solutions, filtered the nanosilver, and treated the cells with the remaining virus solution to determine how many of them would be infected. After several observations, it became clear that nanosilver has an inhibitory activity that depends on the size and number of particles. In the future, detailed studies on the antiviral mechanism of silver nanoparticles could lead to the development of practical means for the destruction of new types of viruses. 
List Of Materials Used:
- Silver Nanoparticles as Potential Antiviral Agents by Stefania Galdiero, Annarita Falanga, Mariateresa Vitiello, Marco Cantisani, Veronica Marra and Massimiliano Galdiero
- Mode of antiviral action of silver nanoparticles against HIV-1. Humberto H Lara, Nilda V Ayala-Nuñez, Liliana Ixtepan-Turrent, Cristina Rodriguez-Padilla4. Silver nanoparticles as potential antiviral agents // Molecules 2011. 16(10). 8894-8918 Galdiero S., Falanga A., Vitiello M., Cantisani M., Marra V., Galdiero M.
- Antiviral activity of silver nanoparticle/chitosan composites against H1N1 influenza A virus. Yasutaka Mori, Takeshi Ono, Yasushi Miyahira, Vinh Quang Nguyen, Takemi Matsui, Masayuki Ishihara
- Valutazione dell’attività antimicrobica di soluzioni antibatteriche Synthag – MicroB Dott. Matteo Sarzi Amadè
- Prove in Vitro per valutare il potere inattivante di sostanze Mask Synthag – Istituto Zooprofilattico Sperimentale della Lombardia e Dell’Emilia Romagna – Dott. Ana Moreno